A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors

BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis. METHODS: Patients with advanced solid tumor were treated with sirolimus for 7 day...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Sehdev, Amikar, Karrison, Theodore, Zha, Yuanyuan, Janisch, Linda, Turcich, Michelle, Cohen, Ezra E. W., Maitland, Michael, Polite, Blase N., Gajewski, Thomas F., Salgia, Ravi, Pinto, Navin, Bissonnette, Marc B., Fleming, Gini F., Ratain, Mark J., Sharma, Manish R.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6739841/
https://ncbi.nlm.nih.gov/pubmed/29948021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3619-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires